The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners.
Minister Mona Keijzer met executives from the RegMedXB private-public partnership, which recently secured funding for up to €56 million from the Dutch National Growth Fund to build an infrastructure of facilities for regenerative therapies in the Netherlands. Regenerative medicine aims to restore or even completely replace the function of failing tissues or organs to reduce or eliminate the need for lifelong treatment.
“Xeltis technology is an excellent example of how the ability to restore heart valve and blood vessels may change patients’ treatment and their lives,” commented Xeltis CEO Eliane Schutte. “The substantial support by the Dutch government to the development of regenerative medicine is an exciting step forward,” she added.
